Title: Efficacy of bronchial artery infusion chemotherapy combined with HDR intraluminal brachytherapy in late stage central lung cancer
Abstract: 【Objective】 To investigate the curative effects,side effects and safety of bronchial artery infusion chemotherapy (BAI) combined with HDR intraluminal brachytherapy for cases with central type of lung cancer in late stage. 【Methods】64 cases were received HDR endobronchial brachytherapy combined with BAI or systemic chemotherapy. Non-small cell lung cancer (NSCLC) chemotherapeutic agents were according to MVP schema, small cell lung cancer (SCLC) according to EP schema, 3~4 weeks as a cycle and 3 cycles as a course. 2 weeks after the first cycle HDR intraluminal brachytherapy by remote after loading system with a high activity source 192Ir after catheter was introduced into the operating channel of flexible bronchoscope and positioned beyond the tumor up to the end of the bronchial tree, cases received four fractions of 6~8 Gy once a week. After the course, the curative ef- fects and side effects were valued. 【Results】 The rate of complete response and total response in the BAI group (75%, 93.75%) was significantly higher than that in the systemic chemotherapy group (50%, 68.75%); and 1 year survival rate 81.25% higher than that in systemic chemotherapy group (43.75%). The amelioration rates according to the symptom and KPS standards in the BAI group (96.875% and 87.50%) were higher than those in systemicchemotherapy group (62.500% and 50.00%). Meanwhile side effects were significantly lower in the BAI group than those in systemic chemotherapy group. 【Conclusion】Bronchial artery infusion of chemotherapeutic agents (BAI) combined with HDR endobronchial brachytherapy for cases with central type of lung cancer in late stage is safe and effective.
Publication Year: 2008
Publication Date: 2008-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot